The molecular and genetic subtyping of cancer has allowed the emergence of individualized therapies. This approach could potentially deliver treatments that have both increased efficacy as well as ...

Universal mismatch repair (MMR) deficiency testing is widely recommended in patients with colorectal cancer (CRC) and others with a family history of MMR deficiency to identify Lynch syndrome, a ...

Treatment of colorectal cancer (CRC)—the third leading cause of cancer-related death in the United States—remains challenging even today. But according to leading oncologists in the field, ...

Introduction Colorectal cancer (CRC) is the third most common cancer and second leading cause of cancer-related death in the United States with more than 149,500 new cases and 52,980 deaths estimated ...

The discovery of immune checkpoints and their role in regulating host immune response to cancer has provided therapeutic targets for clinicians. Although there are now many recognized immune ...

Research from The University of Texas MD Anderson Cancer Center has tried to fill the knowledge gaps that exist in the treatment of colorectal cancers that harbor mutations in genes involved in DNA ...

Keytruda received FDA breakthrough therapy designation for MSI-H mCRC, based on promising phase 2 study results in MMR-deficient patients. The study showed a 62% objective response rate in ...

Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab. Patients with ...

Testing for mismatch repair (MMR) and microsatellite instability (MSI) among patients with colorectal cancer (CRC) increased from 22.7% in 2012 to 71.5% in 2021, but variations in access remain, with ...

Colorectal cancers (CRCs) with deficiency in the mismatch repair (MMR) genes, such as MLH1, MSH2 or MSH6, are classified as Lynch syndrome, and patients with such cancer are at higher risk for other ...